IBTA e-News October 2017 released

By 30th November 2017 January 5th, 2018 News archive
[30 October 2017] The IBTA's monthly e-News has now been released and has been emailed to all subscribers. To sign up to receive your copy, click here.

You can read the IBTA e-News October 2017 edition in full online here.

Some of the highlights from this month's include:

  • The Australian government has announced the launch of the Australian Brain Cancer Mission, which will receive receive AUD $50 million over the next 10 years under the Medical Research Future Fund alongside AUD $50 million contributions from charities and philanthropic partners.
  • The European Commission's Horizon 2020 Research and Innovation Framework Programme has awarded funding of almost €3.9 million to the GLIOTRAIN project, an initiative that will develop a European biomedical research training programme to investigate glioblastoma, training 15 ‘innovative, creative and entrepreneurial’ PhD students.
  • A study in Nature Medicine, has found that the approved chemotherapy agent erlotinib (used in the treatment of pancreatic cancer and non-small cell lung cancer) inhibits glucose processing in glioblastoma cells, making them more vulnerable to other treatments.
  • An international team of researchers has analysed the genetic profiles of over 1,000 paediatric and young adult high-grade gliomas or diffuse intrinsic pontine gliomas (DIPG) and found that these tumours had wide variability in the number of genetic abnormalities, ranging from a single genetic error to tens of thousands – among the highest number of mutations in any human cancer.
  • According to a report published in FESB Journal, researchers have developed a three-dimensional model of the human blood-brain-barrier, which could help in the development and testing of future brain tumour therapies.
  • Researchers from South Africa and the United States have found an association between HIV infection and high grade meningioma (WHO grade II/III) in young adults (under 35 years of age), compared to the general population.
  • Donations to a brain tumour research fund increased from $100,000 to $1.8 million on the day following the death of Gord Downie, the frontman for Canadian rock band Tragically Hip, according to news reports. Gord Downie died from a glioblastoma on October 17, 2017, aged 53.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.